Bavarian initiates new arm of phase III Covid-19 vaccine trial

The first patient has already been dosed in the US, and the Danish vaccine maker is now expanding the study to include Denmark and Belgium.

Photo: Bavarian Nordic / PR

Bavarian Nordic is about to begin the second arm of a phase III study of its Covid-19 vaccine candidate, ABNCoV2, in Denmark and Belgium, the company reports in a press release according to Danish business daily Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs